Corvus Pharmaceuticals's total assets for Q4 2024 were $68.91M, an increase of 17.16% from the previous quarter. CRVS total liabilities were $36.34M for the fiscal quarter, a -21.69% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.